Literature DB >> 23142460

Comparison of flow cytometry and indirect immunofluorescence assay in the diagnosis and cure criterion after therapy of American tegumentary leishmaniasis by anti-live Leishmania (Viannia) braziliensis immunoglobulin G.

Andresa Pereira de Oliveira1, Maria Carolina Accioly Brelaz de Castro, Amanda Ferreira de Almeida, Marina de Assis Souza, Beatriz Coutinho de Oliveira, Luiza Campos Reis, Hiro Goto, Maria Edileuza Felinto de Brito, Beatriz Julieta Celeste, Olindo Assis Martins-Filho, Valéria Rêgo Alves Pereira.   

Abstract

The aim of this study was to compare the techniques of indirect immunofluorescence assay (IFA) and flow cytometry to clinical and laboratorial evaluation of patients before and after clinical cure and to evaluate the applicability of flow cytometry in post-therapeutic monitoring of patients with American tegumentary leishmaniasis (ATL). Sera from 14 patients before treatment (BT), 13 patients 1 year after treatment (AT), 10 patients 2 and 5 years AT were evaluated. The results from flow cytometry were expressed as levels of IgG reactivity, based on the percentage of positive fluorescent parasites (PPFP). The 1:256 sample dilution allowed us to differentiate individuals BT and AT. Comparative analysis of IFA and flow cytometry by ROC (receiver operating characteristic curve) showed, respectively, AUC (area under curve)=0.8 (95% CI=0.64-0.89) and AUC=0.90 (95% CI=0.75-0.95), demonstrating that the flow cytometry had equivalent accuracy. Our data demonstrated that 20% was the best cut-off point identified by the ROC curve for the flow cytometry assay. This test showed a sensitivity of 86% and specificity of 77% while the IFA had a sensitivity of 78% and specificity of 85%. The after-treatment screening, through comparative analysis of the technique performance indexes, 1, 2 and 5 years AT, showed an equal performance of the flow cytometry compared with the IFA. However, flow cytometry shows to be a better diagnostic alternative when applied to the study of ATL in the cure criterion. The information obtained in this work opens perspectives to monitor cure after treatment of ATL. Crown
Copyright © 2012. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23142460     DOI: 10.1016/j.jim.2012.11.002

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  4 in total

Review 1.  Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Authors:  Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Leishmaniases diagnosis: an update on the use of immunological and molecular tools.

Authors:  Milena de Paiva-Cavalcanti; Rayana Carla Silva de Morais; Rômulo Pessoa-E-Silva; Lays Adrianne Mendonça Trajano-Silva; Suênia da Cunha Gonçalves-de-Albuquerque; Diego de Hollanda Cavalcanti Tavares; Maria Carolina Accioly Brelaz-de-Castro; Rafael de Freitas E Silva; Valéria Rêgo Alves Pereira
Journal:  Cell Biosci       Date:  2015-06-17       Impact factor: 7.133

3.  Detection of IgG Anti-Leishmania Antigen by Flow Cytometry as a Diagnostic Test for Cutaneous Leishmaniasis.

Authors:  Geraldo Pedral-Sampaio; Jessé S Alves; Albert Schriefer; Andréa Magalhães; Roberto Meyer; Marshall J Glesby; Edgar M Carvalho; Lucas P Carvalho
Journal:  PLoS One       Date:  2016-09-13       Impact factor: 3.240

4.  American tegumentary leishmaniasis diagnosis using L. (V.) braziliensis fixed promastigotes: a comparative performance of serological tests and spontaneous cure identification.

Authors:  Andresa Pereira Oliveira Mendes; Beatriz Coutinho Oliveira; Allana Maria S Pereira; Maria Carolina Accioly Brelaz Castro; Marina Assis Souza; Maria Edileuza Felinto Brito; Fernanda Fortes Araújo; Andrea Teixeira-Carvalho; Olindo Assis Martins-Filho; Valeria Rêgo Alves Pereira
Journal:  BMC Infect Dis       Date:  2019-11-29       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.